Please assess the completion status of the following clinical trial:

Trial Title: Simvastatin as a Treatment for Pulmonary Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with idiopathic PAH or PAH related to collagen vascular disease~* Age 18 years or over~* Receiving conventional therapy with diuretics, digoxin, warfarin, sildenafil and bosentan. Stable for 1 month~* 6 minute walk distance between 150m and 450m~* Modified NYHA functional class II or III~Exclusion Criteria:~* PAH from a cause other than permitted by entry criteria~* Change in PAH treatment in past 4 weeks~* Patients requiring prostanoid therapy~* Patients already taking a statin~* Clinically significant disturbance of liver function - AST or ALT \>3xULM; bilirubin \>1.5xULM~* Contraindication for a magnetic resonance scan

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Control (Type: PLACEBO_COMPARATOR): Placebo tablet once daily
- Arm 2: Experimental (Type: EXPERIMENTAL): Simvastatin 40mg od for 1 month, then uptitrated to 80mg od for 11 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).